Revance resubmits biologics license application for daxibotulinumtoxina for injection for glabellar lines to the fda

Nashville, tenn.--(business wire)--revance resubmits biologics license application for daxibotulinumtoxina for injection for glabellar lines to the fda

RVNC Ratings Summary

RVNC Quant Ranking